Regeneron Pharmaceuticals paid its 6 named executives $37.2M in total in FY2024 (Dec). CEO Leonard S. Schleifer, M.D., Ph.D. was paid $6.8M of that.
Pay$100 in the stock at the end of FY20 → $147
Pay of each named executive
Daniel P. Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) |
4 years
Andrew J. Murphy, Ph.D.Executive Vice President, Co-Chief Scientific Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) |
4 years
Leonard S. Schleifer, M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) |
4 years
George D. Yancopoulos, M.D., Ph.D.Ph.D. Board co-Chair, President and Chief Scientific Officer
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) |
4 years
Christopher FenimoreExecutive Vice President, Finance and Chief Financial Officer6
| FY2024 (Dec) |
1 year
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 7 peers with pay on file was $28.4M. The CEO of Regeneron Pharmaceuticals was paid $7.3M, 74% below the median.
- 1Eli Lilly & Co
- 2AbbVie
- 3Incyte
- 4Gilead Sciences
- 5Amgen
- 6Bristol Myers Squibb
- 7Merck & Co.
- 8Regeneron PharmaceuticalsThis company
- 9Alnylam Pharmaceuticals, Inc.Not disclosed
- 10BioMarin Pharmaceutical Inc.Not disclosed
- 11BiogenNot disclosed
- 12Vertex Pharmaceuticals IncorporatedNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.